$4.37−0.04 (−0.79%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Alvotech (ALVO) Stock
Alvotech (ALVO) closed at $4.37 on Nov 17, 2026; its Tenet Score is 41 of 100 against 340 Healthcare peers.
Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice
29 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $4.37
- Nov 17, 2026
- Market cap
- $1.4B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- P/E
- 49.2×
- fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
- 52-week range
- 2.94 – 6.53
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 41/100
- Weak · 340 Healthcare peers
Industry: Drugs
Alvotech scores 41/100. Weak. Strongest on growth, financial health is the soft spot, trading at 49× earnings versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value27
Quality29
Health17
Growth90
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityFHealthFGrowthAMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
1.8×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
15.2%
before interest and tax
Net margin
3.6%
fiscal year to Dec 31, 2025
Current ratio
1.89
fiscal year to Dec 31, 2025
Net debt / EBITDA
7.2×
fiscal year to Dec 31, 2025
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
0 / 17
- ✕ Piotroski F-Score
- ✕ Munger Compounders
- ✕ Magic Formula
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
−403.1%
forward EPS growth (consensus) · 3 analystsEarnings
TBA
next reportBeat/miss history appears here after the first tracked report.Statistics
Gross margin51%
Technical Analysis
Mixed short-term signalvs 50-day−15.5%
vs 200-day+5.4%
RSI (14)41
News & Insights
Recent headlines with their publishers and dates.Dividends
Pays no dividend. Every dollar of profit is reinvested into the business.Ownership
No 13F data yet.Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Pacira BioSciences IncPCRX | 56 | $1.5B |
| Intellia Therapeutics IncNTLA | 41 | $1.4B |
| UroGen Pharma LtdURGN | 44 | $1.4B |
| AnaptysBio IncANAB | 53 | $1.4B |
| Novavax, Inc.NVAX | 37 | $1.3B |
| Taysha Gene Therapies IncTSHA | 58 | $1.3B |
| Ocular Therapeutix IncOCUL | 51 | $1.3B |
| Innoviva IncINVA | 73 | $1.3B |
| Absci CorpABSI | 39 | $1.3B |
| Mineralys Therapeutics IncMLYS | 55 | $1.3B |
Common questions
What sector and industry is Alvotech in?
Alvotech is in the Healthcare sector and the Drugs industry.
What is Alvotech's Tenet Score?
Alvotech's Tenet Score is 41 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




